GlassScriptPhysician profile
David Dinuoscio
NPI 1528357571
$90,990.91
in general payments reported to CMS, 2019-2025
36 companies · $81K in 2025
The $81K reported for 2025 was more than what 98% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $524 · 2021: $442 · 2022: $2,048 · 2023: $2,266 · 2024: $3,900 · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Food and Beverage: $8,047 · Travel and Lodging: $2,282 · Consulting Fee: $1,883 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $75,092.40 |
| Food and Beverage | $8,047.06 |
| Travel and Lodging | $2,282.39 |
| Consulting Fee | $1,882.50 |
| Education | $190.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $68,953.60 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $13,079.49 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $3,052.48 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Glaxosmithkline, LLC. | $1,446.51 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $625.64 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.66 | 2019-2025 | Stiolto Respimat, Ofev, Spiriva Respimat |
| Inogen, INC. | $427.50 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Amgen INC. | $405.35 | 2022-2024 | Tezspire |
| Mylan Specialty L.P. | $345.28 | 2022-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $284.13 | 2020-2025 | Glassia |
| Insmed, INC. | $245.76 | 2022-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $215.56 | 2020-2024 | Opsumit |
| Sunovion Pharmaceuticals INC. | $178.86 | 2019-2020 | |
| Pulmonx Corporation | $155.14 | 2021-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Noah Medical Corporation | $134.07 | 2025 | Galaxy |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $123.18 | 2020-2025 | Xolair, Esbriet |
| Electromed, INC. | $115.57 | 2019-2025 | Smartvest |
| Viatris Specialty LLC | $111.81 | 2025 | Yupelri |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Philips North America LLC | $61.99 | 2021-2023 | |
| Baxter Healthcare | $54.79 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $50.69 | 2024 | Winrevair |
| Verona Pharma, INC. | $36.31 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $32.14 | 2025 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $29.15 | 2024 | |
| Idorsia Pharmaceuticals US INC | $26.24 | 2023-2024 | Quviviq |
| Covis Pharma Gmbh | $22.63 | 2022 | |
| Vifor Pharma, INC. | $21.74 | 2025 | Zemaira |
| Harmony Biosciences LLC | $21.53 | 2022 | |
| Axsome Therapeutics, INC. | $19.69 | 2025 | Sunosi |
| Mayne Pharma Commercial LLC | $19.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.08 | 2020 | |
| United Therapeutics Corporation | $14.33 | 2024 | Tyvaso |
| Teva Pharmaceuticals USA, INC. | $13.46 | 2020 | |
| Circassia INC. | $12.93 | 2019 | |
| 3b Medical, INC. | $9.00 | 2025 | Luna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dinuoscio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.